<DOC>
	<DOCNO>NCT00106834</DOCNO>
	<brief_summary>The purpose study determine infliximab ( anti-TNF ) effective treatment plaque psoriasis .</brief_summary>
	<brief_title>A Study Safety Efficacy Infliximab Patients With Psoriasis</brief_title>
	<detailed_description>This experimental medical research study . The purpose study determine infliximab effective treatment plaque psoriasis . A total 375 patient primarily Europe participate study . The time participation study 17 month . Infliximab active drug Remicade . Infliximab currently approve treatment Crohn 's disease ( irritable bowel disease ) , rheumatoid arthritis . The usefulness safety infliximab disease proven previous research study , include 1300 patient North America Europe . In previous small study infliximab 33 patient psoriasis , 80 % patient treat infliximab show improvement psoriasis symptom first 3 infusion , 20 % patient receive placebo show improvement . Patients assign one two treatment group ( Group 1 Group 2 ) . Group 1 receive 5mg/kg infliximab infusion wks 0 , 2 , 4 , 6 , 14 , 22 , 30 , 38 46 placebo infusion wks 24 26 . Group 2 receive placebo infusion wks 0 , 2 , 6 , 10 , 14 , 22 , placebo infusion wks 24 , 26 , 30 , 38 46 . All study medication give though intravenous ( vein ) line . Safety evaluation perform specify interval throughout study consist laboratory test , vital sign ( blood pressure ) , physical examination occurrence severity adverse event well study specific procedure . There 2 different treatment group : Group 1 receive 5mg/kg infliximab infusion wks 0 , 2 , 4 , 6 , 14 , 22 , 30 , 38 46 placebo infusion wks 24 26 . Group 2 receive placebo infusion wks 0 , 2 , 6 , 10 , 14 , 22 , placebo infusion wks 24 , 26 , 30 , 38 46 . All study medication give though intravenous ( vein ) line .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients diagnosis plaquetype psoriasis least 6 month Patients plaquetype psoriasis cover least 10 % body Patients must nonplaque form psoriasis Patients must current druginduced psoriasis Patients must pregnant , nursing , plan pregnancy ( men woman ) within 18 month enrollment Patients must previous treatment infliximab therapeutic agent target reduce TNF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Remicade</keyword>
</DOC>